Form 4: Kairos Pharma CEO John S. Yu Acquires 4,000 Shares

Kairos Pharma's CEO and Chairman, John S. Yu, purchased 4,000 shares of common stock at $1.44 per share on November 20, 2024.

Summary

• John S. Yu, CEO and Chairman of Kairos Pharma, acquired 4,000 shares of the company's common stock.
• The transaction occurred on November 20, 2024.
• The purchase price was $1.44 per share.
• Following the transaction, Mr. Yu directly owns 5,341,837 shares of Kairos Pharma.

Sentiment

Score: 6

Explanation: The document is a routine filing of an insider transaction. It is neither particularly positive nor negative, but the purchase could be seen as a mild positive signal.

Positives

• The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future.

Industry Context

Insider trading activity is closely monitored by investors as it can provide insights into management's view of the company's prospects.

Comparison to Industry Standards

• Insider trading is a common practice, and the reporting of such transactions is a standard requirement for publicly traded companies.
• The size of this transaction is relatively small compared to the total shares owned by the CEO, suggesting it may be a routine purchase rather than a significant shift in ownership.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Kairos Pharma, John S. Yu, insider trading, share purchase, common stock, KAPA, CEO, ownership